Exponent Inc (EXPO)

Return on equity (ROE)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 109,002 106,342 104,836 101,357 100,339 101,934 101,838 101,845 102,330 100,186 100,318 99,963 101,202 102,662 96,172 87,118 82,552 79,833 81,382 86,030
Total stockholders’ equity US$ in thousands 421,068 410,274 393,213 374,311 356,085 353,635 357,079 341,856 320,752 319,800 337,494 386,564 417,065 404,989 387,767 377,608 361,498 343,197 332,567 323,497
ROE 25.89% 25.92% 26.66% 27.08% 28.18% 28.82% 28.52% 29.79% 31.90% 31.33% 29.72% 25.86% 24.27% 25.35% 24.80% 23.07% 22.84% 23.26% 24.47% 26.59%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $109,002K ÷ $421,068K
= 25.89%

Exponent Inc's return on equity (ROE) has demonstrated a generally positive trend over the period from March 31, 2020, to December 31, 2024. Starting at 26.59% in March 2020, the ROE decreased slightly to 22.84% by December 2020 before gradually increasing over the subsequent quarters. The ROE saw a notable rise to 31.90% by December 2022, indicating improved profitability relative to shareholders' equity.

However, from March 2023 onwards, the ROE began to decline, falling to 25.89% by December 2024. This downward trend suggests that the company's efficiency in generating profits from shareholders' equity weakened during this period.

Overall, while the ROE initially showed positive improvement before reaching a peak in late 2022, the subsequent decline in the metric may indicate a need for Exponent Inc to focus on enhancing its profitability in relation to shareholders' investments. Tracking the ROE over time can provide valuable insights into the company's financial performance and its ability to generate returns for equity investors.


Peer comparison

Dec 31, 2024

Company name
Symbol
ROE
Exponent Inc
EXPO
25.89%
FTI Consulting Inc
FCN
12.40%
Genpact Limited
G
21.50%